ACP001

Unassigned

New Medicines

Treatment of growth hormone deficiency in children and adults

Information

New molecular entity
Ascendis Pharma
Ascendis Pharma

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Sustained-release prodrug of somatropin (human growth hormone) for weekly use - consists of a polyethylene glycol (PEG) moiety linked to somatropin via a hydrolysable linker.
Adult GH deficiency has been estimated to affect 1 in 100,000 people annually, while its incidence rate is approximately 2 cases per 100,000 population when childhood-onset GH deficiency patients are considered. About 15-20 % of the cases represent the transition of childhood GH deficiency into adulthood [1].
Treatment of growth hormone deficiency in children and adults
Subcutaneous injection